Table 1.
Patient characteristics of primary AML patient samples.
| Patient | Gender | Age (year) | Disease status | FAB subtype | Cytogenetics | Blast purity (%) | Gene mutation |
|---|---|---|---|---|---|---|---|
| #1 | M | 17 | Newly diagnosed | M2 | 46, XY | 68.5 | CEBPA double mutation |
| #2 | F | 76 | Newly diagnosed | M5 | 46, XX | 84.5 | dupMLL, CEBPA signal mutation |
| #3 | M | 52 | Newly diagnosed | M4 | 46, XY | 96 | DEK-CAN |
| #4 | M | 65 | Newly diagnosed | M5 | 47, XY, add(7q), −16, −17, +marx3 | 76 | |
| #5 | M | 43 | Newly diagnosed | M2 | 46, XY, t(8;21)(q22;q22) | 48 | AML1-ETO |
| #6 | M | 50 | Newly diagnosed | M2 | 45, X, −Y, t(8;21)(q22;q22), del(11q) | 46 | AML1-ETO |
| #7 | M | 12 | Newly diagnosed | M3 | 46, XY, t(15;17)(q22;q21) | 92.5 | PML-RARα |
| #8 | M | 74 | Newly diagnosed | M5 | 47, XY,+8 | 95 | FLT-3 ITD, NPM-1, DNMT3A |
| #9 | M | 19 | Newly diagnosed | M2 | 45, X, −Y, t(8;21)(q22;q22), del(9q) | 47 | AML1-ETO |
| #10 | M | 25 | Newly diagnosed | M3 | 46, XY, t(15;17)(q22;q21) | 94 | PML-RARα |
| #11 | M | 48 | Relapsed | M2 | 46, XY, t(7;11)(p15;p15) | 39.5 | FLT-3 ITD |
| #12 | F | 9 | Newly diagnosed | M1 | NA | 93.5 | |
| #13 | F | 50 | Relapsed | M2 | 46, XX | 81 | CEBPA double mutation |
| #14 | F | 7 | Newly diagnosed | M4 | 46, XX, t(11;20)(p15;q11)/46, idem, del(9) (q22) | 83 | EVI1 |
| #15 | F | 52 | Newly diagnosed | M3 | 46, XX, t(15;17)(q22;q21) | 90 | PML-RARα |
| #16 | M | 38 | Newly diagnosed | M3 | 47, XY, add(1p), t(15;17)(q22;q21), +14 | 95 | PML-RARα |
| #17 | M | 34 | Newly diagnosed | M2 | 46, XY | 29 | FLT-3 ITD, dupMLL |
| #18 | F | 51 | Newly diagnosed | M5 | 46, XX | 82 | |
| #19 | M | 48 | Newly diagnosed | M5 | 46, XY | 42 | IDH2, DNMT3A |
| #20 | F | 77 | Newly diagnosed | M4 | 46, XX | 50 | |
| #21 | F | 44 | Newly diagnosed | M3 | 46, XX, t(15;17)(q22;q21) | 89 | PML-RARα |
| #22 | F | 12 | Newly diagnosed | M2 | 47, XX, +10 | 80 | FLT-3 ITD, CEBPα single mutation |
| #23 | F | 60 | Newly diagnosed | M5 | 46, XX | 69.5 | |
| #24 | F | 32 | Newly diagnosed | M4 | 46, XX, del(9q) | 27 | CEBPA double mutation |
| #25 | F | 65 | Newly diagnosed | M5 | 46, XX | 91 | Flt-3 ITD, NPM-1 |
| #26 | M | 18 | Newly diagnosed | M3 | 46, XY, t(15;17)(q22;q21) | 95 | PML-RARα |
| #27 | M | 64 | Newly diagnosed | M4 | 46, XY | 69 | |
| #28 | M | 59 | Newly diagnosed | M2 | 46, XY | 82 | HOX11 |
| #29 | F | 75 | Newly diagnosed | M4 | 46, XX, +8 | 91 | |
| #30 | F | 54 | Newly diagnosed | M5 | 46, XX | 64 | MLL-AF6 |
| #31 | F | 48 | Newly diagnosed | M6 | 45, XX, del(3q), −7 | 39 | |
| #32 | F | 35 | Newly diagnosed | M2 | 45, X, −X, t(8;21)(q22;q22) | 22.5 | AML1-ETO, FLT-3 ITD |
| #33 | F | 64 | Newly diagnosed | M4 | NA | 91 | dupMLL, FLT-3 ITD, IDH1 |
| #34 | M | 76 | Newly diagnosed | M4 | 46, XY | 95.5 | |
| #35 | F | 46 | Newly diagnosed | M2 | 46, XX | 64.5 | MDS |
| #36 | F | 50 | Newly diagnosed | M4 | 46, XX | 91.5 | FLT-3 ITD, NPM-1, DNMT3A |
| #37 | F | 69 | Newly diagnosed | M1 | 46, XX | 91.5 | |
| #38 | F | 59 | Newly diagnosed | M4 | 46, XX | 82.0 | CEBPA double mutation |
| #39 | F | 14 | Newly diagnosed | M2 | 46, XX | 34.0 | CEBPA double mutation |
| #40 | M | 65 | Newly diagnosed | M4 | 46, XY | 86.0 | FLT-3 ITD, DNMT3A, IDH2 |
| #41 | M | 55 | Newly diagnosed | M3 | 46, X, −Y, t(15;17)(q22;q21) | 93.0 | PML-RARα |
| #42 | M | 27 | Newly diagnosed | M3 | 46, X, Y, t(15;17)(q22;q21) | 94,0 | FLT-3 ITD, PML-RARα |
| #43 | F | 66 | Relapsed | M4 | 45, XX, −7 | 48.0 | |
| #44 | M | 19 | Newly diagnosed | M4 | 46, XY | 63 | CEBPA, c-Kit, NRAS, GATA2, Flt3 S451F |
| #45 | M | 77 | Newly diagnosed | M4 | NA | NA | NA |
| #46 | M | 53 | Relapsed | M2 | NA | 98.0 | |
| #47 | F | 62 | Newly diagnosed | M1 | NA | 98.50 | RUNX1 、 BCOR 、 FLT3 |
| #48 | F | 4 | Newly diagnosed | M2 | 46, XX, t(8;21)(q22;q22) | 26.00 | N-RAS |
| #49 | F | 55 | Newly diagnosed | M1 | 46, XX | 98.00 | K-RAS |
| #50 | F | 38 | Newly diagnosed | M4 | 46, XX | 87.00 | FLT3-ITD 、 DNMT3A |